Mibefradil, used for cancer treatment, is a T-type calcium channel blocker which arrests tumor cells at their most vulnerable metabolic point.
TAU Therapeutics is developing Mibefradil.
Scynexis and PharmaDirections have involved in the process and analytical development and GMP manufacturing of mibefradil since 2010.
The companies worked on minimizing or eliminating the impurities found in the original manufacturing process.